IPO Year: 2026
Exchange: NASDAQ
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)
SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)
8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)
Fastest customizable press release news feed in the world
SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales. The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, t
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at the initial public offering price of $16.00 per share. All of the shares of common stock were offered by Kailera. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $718.8 million. Kailera's